Conditions: Carcinoid Syndrome; Carcinoid Tumor; Digestive System Neuroendocrine Tumor G1; Metastatic Carcinoid Tumor
Intervention: Procedure: Dual-Energy Computed Tomography
Sponsor: M.D. Anderson Cancer Center
Recruiting
Feeds
6810 items (6810 unread) in 74 feeds
Acinar Cell Carcinoma
(81 unread)
Acinic Cell Carcinoma
(46 unread)
Adenoid Cystic Carcinoma
(159 unread)
Adrenal Gland Cancer
(533 unread)
Ampulla Of Vater
(68 unread)
Anal Cancer
(425 unread)
Angiosarcoma
(153 unread)
Appendix Cancer
(104 unread)
Bile Duct Cancer
(845 unread)
Brain and CNS
(878 unread)
Carcinoid
(266 unread)
Endocrine/Neuroendocrine
(808 unread)
Gall Bladder Cancer
(381 unread)
Hemangioendothelioma
(215 unread)
Hepatoblastoma
(129 unread)
Pancreas
(117 unread)
Phyllodes
(105 unread)
PMP and Mucinous Tumors
(114 unread)
Rhabdomyosarcoma
(246 unread)
Sarcoma
(1137 unread)
Trials - Carcinoid (39 unread)
-
An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors
Posted: August 6th, 2021, 2:00pm GMT
-
Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors
Posted: December 17th, 2020, 3:00pm GMT
Condition: Neuroendocrine Tumors
Intervention: Drug: Telotristat Ethyl Oral Tablet
Sponsor: University of Chicago
Not yet recruiting -
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Posted: December 14th, 2020, 3:00pm GMT
Conditions: Advanced Lung Carcinoid Tumor; Functioning Lung Carcinoid Tumor; Locally Advanced Lung Neuroendocrine Neoplasm; Lung Atypical Carcinoid Tumor; Lung Neuroendocrine Neoplasm; Lung Typical Carcinoid Tumor; Metastatic Lung Carcinoid Tumor; Metastatic Lung Neuroendocrine Neoplasm; Non-Functioning Lung Carcinoid Tumor; Recurrent Lung Neuroendocrine Neoplasm; Unresectable Lung Carcinoid Tumor; Unresectable Lung Neuroendocrine Neoplasm
Interventions: Drug: Everolimus; Drug: Lutetium Lu 177 Dotatate
Sponsor: National Cancer Institute (NCI)
Not yet recruiting -
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
Posted: August 24th, 2020, 2:00pm GMT
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Intervention: Drug: arginine/lysine
Sponsor: Advanced Accelerator Applications
Recruiting -
Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.
Posted: February 19th, 2020, 3:00pm GMT
Conditions: Pulmonary Neuroendocrine Neoplasm; Pheochromocytoma; Paraganglioma; Thymus Carcinoid; Unknown Primary Tumors; Neuroendocrine Tumors; Neuroendocrine Skin Carcinoma; Neuroendocrine Breast Tumor; Neuroendocrine Carcinoma Metastatic; Neuroendocrine Neoplasm of Ovary
Intervention: Drug: 177Lu-DOTATOC
Sponsor: Excel Diagnostics and Nuclear Oncology Center
Recruiting -
Cabozantinib and Nivolumab for Carcinoid Tumors
Posted: December 13th, 2019, 3:00pm GMT
Conditions: Carcinoid Tumor; Carcinoid Tumor of GI System; Neuroendocrine Tumors
Interventions: Drug: Nivolumab; Drug: Cabozantinib
Sponsors: Dana-Farber Cancer Institute; Bristol-Myers Squibb; Exelixis
Recruiting -
Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer
Posted: December 11th, 2019, 3:00pm GMT
Condition: Neuroendocrine Tumors
Intervention: Drug: 177Lu-DOTATOC
Sponsors: University of Warmia and Mazury; Maria Sklodowska-Curie Institute - Oncology Center; Medical University of Warsaw; The Diagnostic and Therapeutic Center Gammed; Poland; National Center for Research and Development, Poland
Recruiting -
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Posted: September 11th, 2019, 2:00pm GMT
Conditions: Gastroenteropancreatico Tumors; Neuroendocrine Tumors; Neuroendocrine Neoplasms
Interventions: Drug: Lu-177-DOTATATE; Drug: Olaparib; Diagnostic Test: Ga dotatate scanning; Diagnostic Test: FDG-PET scanning
Sponsor: National Cancer Institute (NCI)
Not yet recruiting -
Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy
Posted: July 31st, 2019, 2:00pm GMT
Conditions: Carcinoid Heart Disease; Carcinoid Syndrome; Carcinoid Tumor
Intervention: Drug: Lutathera
Sponsors: King's College Hospital NHS Trust; Advanced Accelerator Applications
Not yet recruiting -
Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression
Posted: July 23rd, 2019, 2:00pm GMT
Condition: Neuroendocrine Tumors
Interventions: Drug: 90Y-DOTATATE; Drug: (177Lu-DOTAOTyr3)Octreotate; Drug: 90Y DOTATATE and 177Lu DOTATATE (mix each of 50%)
Sponsors: University of Warmia and Mazury; Stowarzyszenie Pacjentów i Osób Wspierających Chorych na Guzy Neuroendokrynne
Recruiting -
The Registry of Oncology Outcomes Associated With Testing and Treatment
Posted: July 22nd, 2019, 2:00pm GMT
Conditions: Adenocarcinoma; Adenocystic Carcinoma; Anal Cancer; Appendix Cancer; Brain Tumor; Glioblastoma; Astrocytoma; Bile Duct Cancer; Cholangiocarcinoma; Bladder Cancer; Bone Cancer; Synovial Sarcoma; Chondrosarcoma; Liposarcoma; Sarcoma, Kaposi; Sarcoma,Soft Tissue; Sarcoma; Osteosarcoma; CNS Cancer; Brain Stem Neoplasms; Breast Cancer; Cervical Cancer; Colorectal Cancer; Rectal Cancer; Colon Cancer; Esophageal Cancer; Esophagus Cancer; Cancer of Colon; Pancreatic Cancer; Cancer of Pancreas; Testis Cancer; Testicular Cancer; Ureter Cancer; Renal Cell Carcinoma; Kidney Cancer; Gestational Trophoblastic Tumor; Head and Neck Neoplasms; Parotid Tumor; Larynx Cancer; Tongue Cancer; Pharynx Cancer; Salivary Gland Cancer; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia; Multiple Myeloma; Non Hodgkin Lymphoma; Carcinoid Tumor; Lung Cancer; Neuroendocrine Tumors; Mesothelioma; Thyroid Cancer; Parathyroid Neoplasms; Adrenal Cancer; Small Bowel Cancer; Stomach Cancer; Liver Cancer; Hepatic Cancer; Melanoma; Skin Cancer; Unknown Primary Tumors; Uterine Cancer; Fallopian Tube Cancer; Ovarian Cancer; Prostate Cancer; Vaginal Cancer; Penile Cancer; Vulvar Cancer; Waldenstrom Macroglobulinemia; Cancer, Advanced; Thymus Cancer; Nasopharyngeal Carcinoma; Multiple Endocrine Neoplasia; Pheochromocytoma; Small Cell Carcinoma; Pulmonary Carcinoma
Interventions: Diagnostic Test: Biomarker Testing (L); Drug: Systemic Treatment (T); Other: Patient Reported Outcomes (P)
Sponsor: Taproot Health
Not yet recruiting -
Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging
Posted: July 12th, 2019, 2:00pm GMT
Conditions: Neuroendocrine Tumors; Prostate Cancer; Prostatic Neoplasms; Carcinoid Tumor; Paraganglioma; Neuroblastoma
Interventions: Diagnostic Test: 18F-FDG PET/CT; Diagnostic Test: 68Ga-DOTATOC PET/CT; Diagnostic Test: 18F-DCFPyL PET/CT
Sponsor: British Columbia Cancer Agency
Recruiting -
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
Posted: May 15th, 2019, 2:00pm GMT
Conditions: Advanced Carcinoid Tumor; Digestive System Neuroendocrine Neoplasm; Multiple Endocrine Neoplasia Type 1; Neuroendocrine Neoplasm; Unresectable Carcinoid Tumor
Interventions: Drug: Everolimus; Drug: Lenvatinib
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting -
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
Posted: March 27th, 2019, 2:00pm GMT
Conditions: Advanced Digestive System Neuroendocrine Neoplasm; Digestive System Neuroendocrine Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm; Metastatic Digestive System Neuroendocrine Neoplasm; Midgut Neuroendocrine Tumor G1; Pancreatic Neuroendocrine Tumor; Refractory Digestive System Neuroendocrine Neoplasm
Intervention: Drug: Abemaciclib
Sponsors: University of Washington; Eli Lilly and Company
Recruiting -
Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
Posted: March 19th, 2019, 2:00pm GMT
Conditions: Lung Atypical Carcinoid Tumor; Lung Typical Carcinoid Tumor; Metastatic Pancreatic Neuroendocrine Tumor
Interventions: Biological: Incomplete Freund's Adjuvant; Drug: Octreotide Acetate; Biological: Sargramostim; Biological: SVN53-67/M57-KLH Peptide Vaccine
Sponsors: Roswell Park Cancer Institute; NeuroEndocrine Tumor Research Foundation (NETRF)
Recruiting -
Chromogranin A as Blood Marker in Cancer Patients
Posted: January 28th, 2019, 3:00pm GMT
Conditions: Gastric Neoplasms; Pancreatic Neoplasms; Small Intestinal Neoplasms; Colorectal Neoplasms
Intervention: Diagnostic Test: BRAHMS CgA II KRYPTOR
Sponsor: Brahms AG
Recruiting -
Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs
Posted: October 29th, 2018, 2:00pm GMT
Conditions: Neuroendocrine Tumors; Carcinoid Tumor of GI System; Diarrhea; Carcinoid Syndrome
Intervention: Dietary Supplement: Amino Acid Based Medical Food/Drink
Sponsors: Lowell Anthony, MD; Entrinsic Bioscience Inc.
Recruiting -
Bronchoscopic Laser Ablation of Peripheral Lung Tumors
Posted: October 16th, 2018, 2:00pm GMT
Conditions: Lung Carcinoid Tumor; Lung Non-Small Cell Carcinoma; Metastatic Lung Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
Interventions: Procedure: Cone-Beam Computed Tomography; Procedure: Conventional Surgery; Procedure: Laser Ablation
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting -
Clinic, Pathologic and Genetic Characterization of Patients With Familial Carcinoid Tumors (Study From the GTE, Groupe d'étude Des Tumeurs Endocrines)
Posted: August 9th, 2018, 2:00pm GMT
Condition: Small Intestinal Carcinoid Tumors
Intervention: Genetic: Research of constitutional genetic alterations
Sponsor: CHU de Reims
Recruiting -
Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers
Posted: August 9th, 2018, 2:00pm GMT
Conditions: Neuroendocrine Carcinoma of Pancreas; Carcinoid
Intervention: Drug: Gallium Dotatate
Sponsor: University of Alabama at Birmingham
Recruiting -
DOTATOC PET/CT for Imaging NET Patients
Posted: July 11th, 2018, 2:00pm GMT
Conditions: Neuroendocrine Tumors; Insulinoma; Gastrinoma; Glucagonoma; Vipoma; Pheochromocytoma; Paraganglioma; Neuroblastoma; Ganglioneuroma; Medullary Carcinoma; Pituitary Adenoma; Medulloblastoma; Merkel Cell Carcinoma; Small-cell Lung Cancer; Meningioma; Carcinoid
Interventions: Diagnostic Test: 68Ga-DOTATOC PET/CT; Diagnostic Test: 18F-FDG PET/CT
Sponsor: British Columbia Cancer Agency
Recruiting -
Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine Tumors
Posted: April 13th, 2018, 2:00pm GMT
Condition: Carcinoid Heart Disease
Intervention: Other: Study of the occurrence of Carcinoid Heart Disease
Sponsor: Hospices Civils de Lyon
Not yet recruiting -
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Posted: December 18th, 2017, 3:00pm GMT
Conditions: Atypical Carcinoid Tumor; Carcinoid Tumor; Functioning Pancreatic Neuroendocrine Tumor; Intermediate Grade Lung Neuroendocrine Neoplasm; Locally Advanced Pancreatic Neuroendocrine Tumor; Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm; Low Grade Lung Neuroendocrine Neoplasm; Lung Atypical Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Neoplasm; Metastatic Digestive System Neuroendocrine Tumor G1; Metastatic Pancreatic Neuroendocrine Tumor; Metastatic Thymic Neuroendocrine Neoplasm; Neuroendocrine Neoplasm; Non-Functioning Pancreatic Neuroendocrine Tumor; Pancreatic Serotonin-Producing Neuroendocrine Tumor; Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7; Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7; Stage IV Digestive System Neuroendocrine Tumor AJCC v7
Interventions: Drug: Cabozantinib S-malate; Other: Laboratory Biomarker Analysis; Other: Placebo Administration; Other: Quality-of-Life Assessment
Sponsor: National Cancer Institute (NCI)
Recruiting -
Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO
Posted: July 21st, 2017, 2:00pm GMT
Condition: Carcinoid Syndrome
Intervention: Drug: Xermelo
Sponsor: TerSera Therapeutics LLC
Recruiting -
MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents
Posted: July 13th, 2017, 2:00pm GMT
Condition: Neuroendocrine Tumors
Interventions: Drug: Oxaliplatin-based chemotherapy; Drug: Alkylating-based chemotherapy
Sponsor: Hospices Civils de Lyon
Recruiting -
Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
Posted: April 12th, 2017, 2:00pm GMT
Conditions: Lung Atypical Carcinoid Tumor; Lung Neuroendocrine Neoplasm; Lung Non-Small Cell Squamous Carcinoma; Minimally Invasive Lung Adenocarcinoma; Neuroendocrine Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Lung Large Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage IA1 Lung Cancer AJCC v8; Stage IA2 Lung Cancer AJCC v8; Stage IA3 Lung Cancer AJCC v8; Stage IB Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8
Interventions: Biological: Nivolumab; Radiation: Stereotactic Body Radiation Therapy
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting -
Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin
Posted: March 29th, 2017, 2:00pm GMT
Conditions: Neuroendocrine Tumors; Neuroendocrine Neoplasm of Lung
Interventions: Drug: Durvalumab; Drug: Tremelimumab
Sponsor: Grupo Espanol de Tumores Neuroendocrinos
Recruiting -
Thoracic Tumours Register
Posted: October 21st, 2016, 2:00pm GMT
Condition: Thoracic Tumors
Intervention:
Sponsor: Spanish Lung Cancer Group
Recruiting -
A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Posted: August 23rd, 2016, 2:00pm GMT
Conditions: Lymphoma, Non-Hodgkin; Neoplasms
Intervention: Drug: CC-90011
Sponsor: Celgene
Recruiting -
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Posted: July 15th, 2016, 2:00pm GMT
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Breast Metaplastic Carcinoma; Cervical Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Solid Neoplasm; Malignant Testicular Sex Cord-Stromal Tumor; Metastatic Malignant Neoplasm of Unknown Primary; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
Interventions: Procedure: Biospecimen Collection; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting -
Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors
Posted: July 11th, 2016, 2:00pm GMT
Condition: Small-intestine Neuroendocrine Tumors (Carcinoid Tumors)
Intervention: Biological: blood sample withdrawn
Sponsor: CHU de Reims
Recruiting -
Personalized PRRT of Neuroendocrine Tumors
Posted: April 28th, 2016, 2:00pm GMT
Conditions: Neuroendocrine Tumors; Carcinoid Tumor; Carcinoma, Neuroendocrine
Intervention: Drug: 177Lu-Octreotate
Sponsor: CHU de Quebec-Universite Laval
Recruiting -
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Posted: December 11th, 2015, 3:00pm GMT
Conditions: Advanced Cancer; Anal Carcinoma; Anal Cancer; Biliary Cancer; Cholangiocarcinoma; Bile Duct Cancer; Neuroendocrine Tumor; Carcinoid Tumor; Endometrial Carcinoma; Endometrial Cancer; Cervical Carcinoma; Cervical Cancer; Vulvar Carcinoma; Vulvar Cancer; Small Cell Lung Carcinoma; Small Cell Lung Cancer (SCLC); Mesothelioma; Thyroid Carcinoma; Thyroid Cancer; Salivary Gland Carcinoma; Salivary Gland Cancer; Salivary Cancer; Parotid Gland Cancer; Advanced Solid Tumors; Colorectal Carcinoma
Intervention: Biological: pembrolizumab
Sponsor: Merck Sharp & Dohme Corp.
Recruiting -
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
Posted: September 15th, 2015, 2:00pm GMT
Condition: Tumors
Intervention: Drug: surufatinib
Sponsor: Hutchison Medipharma Limited
Recruiting -
18F-FDOPA PET in Neuroendocrine Tumours
Posted: May 1st, 2015, 2:00pm GMT
Conditions: Thyroid Cancer, Medullary; Carcinoid Tumor; Pheochromocytoma; Paraganglioma; Insulinoma; Neuroblastoma
Intervention: Drug: [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)
Sponsor: British Columbia Cancer Agency
Available -
SwissNET - a Registry for Neuroendocrine Tumours in Switzerland
Posted: December 25th, 2009, 3:00pm GMT
Conditions: Neuroendocrine Tumors; Carcinoid Tumor
Intervention:
Sponsors: University Hospital Inselspital, Berne; Cantonal Hospital of St. Gallen; University Hospital, Basel, Switzerland; University Hospital, Geneva; University of Lausanne Hospitals; University Hospital, Zürich; Triemlispital Zurich; Spitalnetz Bern; Ente Ospedaliero Cantonale, Bellinzona; Luzerner Kantonsspital; Kantonsspital Liestal; Kantonsspital Graubuenden; Spital Limmattal Schlieren; Waid City Hospital, Zurich; Spital STS AG
Recruiting -
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
Posted: September 30th, 2009, 2:00pm GMT
Conditions: Cancer Metastatic to the Liver; Hepatocellular Carcinoma; Metastatic Melanoma; Metastatic Ocular Melanoma; Metastatic Uveal Melanoma; Metastatic Lung Cancer; Metastatic Colon Cancer; Metastatic Colorectal Cancer; Metastatic Breast Cancer; Metastatic Pancreatic Cancer
Intervention: Drug: PV-10 (10% rose bengal disodium)
Sponsor: Provectus Biopharmaceuticals, Inc.
Recruiting -
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
Posted: May 12th, 2009, 2:00pm GMT
Conditions: Esophageal Cancer; Head and Neck Cancer; Lung Cancer; Precancerous Condition
Interventions: Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: sputum cytology; Procedure: biopsy
Sponsors: University of Colorado, Denver; National Cancer Institute (NCI)
Recruiting -
DNA Analysis of Blood and Tissue From Patients With Lung Cancer
Posted: May 10th, 2007, 2:00pm GMT
Condition: Lung Cancer
Intervention:
Sponsors: Massachusetts General Hospital; National Cancer Institute (NCI)
Recruiting